Aktuelle News
News Funktionen
Weitere Funktionen
26 März 2024
SphingoTec GmbH
SphingoTec Announces Management Changes
5 Oktober 2023
SphingoTec GmbH
New Formula Leverages Proenkephalin A 119-159 (penKid) for Improved GFR Estimation in Steady-State and Critically Ill Patients
6 September 2023
SphingoTec GmbH
International Experts Highlight Demand for Diagnostic Innovations as PenKid’s Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools
31 August 2023
SphingoTec GmbH
Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid
9 Mai 2023
SphingoTec GmbH
SphingoTec’s Innovative IVD Product sphingotest® penKid® Receives First IVDR Certificate
4 April 2023
SphingoTec GmbH
ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury
23 Februar 2023
SphingoTec GmbH
SphingoTec Appoints Dr. Florian Uhle as Medical Director
15 Dezember 2022
SphingoTec GmbH
Liberation from renal replacement therapy and early initiation to be supported by the kidney function biomarker Proenkephalin A 119-159 (penKid)
15 November 2022
SphingoTec GmbH
Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)
26 August 2022
SphingoTec GmbH
Abteilungsübergreifende Testung des Nierenbiomarkers penKid in der Routineversorgung des Universitätsklinikums Heidelberg und dem Nierenzentrum Heidelberg
8 August 2022
SphingoTec GmbH
Medical thought leaders in critical care aim to advance precision medicine using biomarker-based approaches
1 August 2022
SphingoTec GmbH
Endothelial function biomarker bioactive Adrenomedullin (bio-ADM) enables triage of sepsis patients in the emergency department
30 Juni 2022
SphingoTec GmbH
SphingoTec appoints Jörg Menten as CEO to accelerate commercialization and global growth
11 April 2022
SphingoTec GmbH
Biomarker-gesteuerte Studie unter Leitung des Universitätsklinikums Hamburg-Eppendorf (UKE) eröffnet neue Wege für personalisierte Medizin bei COVID-19
24 März 2022
SphingoTec GmbH
The Biomarkers bio-ADM and DPP3 Complement Post-Cardiac Surgery Diagnostics to Early Detect Organ Failure
17 März 2022
SphingoTec GmbH
SphingoTec and Rivaara Labs Close Exclusive Distribution Agreement for Point of Care Diagnostics in India
15 März 2022
SphingoTec GmbH
Proenkephalin (penKid) sheds light on the diagnostic blind spots in assessing acute kidney injury in children
29 November 2021
SphingoTec GmbH
SphingoTec Appoints Jörg Menten to Leadership Team as Chief Commercial Officer to Drive New Business Growth
9 September 2021
SphingoTec GmbH
SphingoTec’s innovative biomarkers to enable personalized medicine in septic organ failure
31 August 2021
SphingoTec GmbH
New data on innovative biomarkers used to guide the clinical management of septic patients
23 August 2021
SphingoTec GmbH
SphingoTec Appoints Dr. Gerald Möller as Chairman of the Advisory Board
10 Juni 2021
SphingoTec GmbH
SphingoTec Expands Management Team and Appoints new CFO
20 Mai 2021
SphingoTec GmbH
SphingoTec Accelerates Growth with Direct Sales
4 Mai 2021
SphingoTec GmbH
Endothelial Function Biomarker bio-ADM to Support Risk Stratification and Clinical Management of COVID-19 Patients
23 März 2021
SphingoTec GmbH
SphingoTec GmbH: New diagnostic tool for the management of patients with sepsis: Dipeptidyl Peptidase 3 (DPP3)
18 Februar 2021
SphingoTec GmbH
Two distinct pathways leading to the development of septic shock pave the way for personalized medicine in sepsis
16 Dezember 2020
SphingoTec GmbH
Proenkephalin (penKid(R)) included in the ADQI consensus statements publication as functional kidney biomarker for the management of AKI patients
10 Dezember 2020
SphingoTec GmbH
Uniklinik RWTH Aachen implementiert als erste Klinik SphingoTec’s innovative Biomarker in der klinischen Routine mit dem Ziel die intensivmedizinische Diagnostik zu präzisieren
29 September 2020
SphingoTec GmbH
SphingoTec GmbH: SphingoTec, BHR Pharmaceuticals ink agreement for distribution of SphingoTec’s acute care portfolio in the UK and Ireland
27 August 2020
SphingoTec GmbH
SphingoTec’s kidney function biomarker penKid(R) accurately detects acute kidney injury in infants